GB9902555D0 - Medicament - Google Patents

Medicament

Info

Publication number
GB9902555D0
GB9902555D0 GBGB9902555.3A GB9902555A GB9902555D0 GB 9902555 D0 GB9902555 D0 GB 9902555D0 GB 9902555 A GB9902555 A GB 9902555A GB 9902555 D0 GB9902555 D0 GB 9902555D0
Authority
GB
United Kingdom
Prior art keywords
prevention
medicament
treatment
atherosclerosis
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9902555.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutec Pharma Ltd
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Priority to GBGB9902555.3A priority Critical patent/GB9902555D0/en
Publication of GB9902555D0 publication Critical patent/GB9902555D0/en
Priority to EP00901235A priority patent/EP1149162B1/fr
Priority to AU21192/00A priority patent/AU2119200A/en
Priority to PCT/GB2000/000237 priority patent/WO2000046359A2/fr
Priority to CA002359354A priority patent/CA2359354C/fr
Priority to AT00901235T priority patent/ATE425248T1/de
Priority to DE60041753T priority patent/DE60041753D1/de
Priority to US10/634,914 priority patent/US7132512B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
GBGB9902555.3A 1999-02-05 1999-02-05 Medicament Ceased GB9902555D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB9902555.3A GB9902555D0 (en) 1999-02-05 1999-02-05 Medicament
EP00901235A EP1149162B1 (fr) 1999-02-05 2000-01-28 Medicament pour le traitement des infections a c. pneumoniae
AU21192/00A AU2119200A (en) 1999-02-05 2000-01-28 Medicament
PCT/GB2000/000237 WO2000046359A2 (fr) 1999-02-05 2000-01-28 Medicament
CA002359354A CA2359354C (fr) 1999-02-05 2000-01-28 Medicament pour le traitement, la prevention et le diagnostic d'une infection due a chlamydia pneumoniae
AT00901235T ATE425248T1 (de) 1999-02-05 2000-01-28 Arzneimittel zur behandlung von c. pneumoniae infektionen
DE60041753T DE60041753D1 (de) 1999-02-05 2000-01-28 Arzneimittel zur behandlung von c. pneumoniae infektionen
US10/634,914 US7132512B2 (en) 1999-02-05 2003-08-06 Medicament for the treatment of chlamydial infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9902555.3A GB9902555D0 (en) 1999-02-05 1999-02-05 Medicament

Publications (1)

Publication Number Publication Date
GB9902555D0 true GB9902555D0 (en) 1999-03-24

Family

ID=10847149

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9902555.3A Ceased GB9902555D0 (en) 1999-02-05 1999-02-05 Medicament

Country Status (8)

Country Link
US (1) US7132512B2 (fr)
EP (1) EP1149162B1 (fr)
AT (1) ATE425248T1 (fr)
AU (1) AU2119200A (fr)
CA (1) CA2359354C (fr)
DE (1) DE60041753D1 (fr)
GB (1) GB9902555D0 (fr)
WO (1) WO2000046359A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340283A1 (fr) 1998-08-20 2000-03-02 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine pomp91a de chlamydia
CA2340330A1 (fr) 1998-08-20 2000-03-02 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine membrane d'inclusion c de chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
KR20090088972A (ko) 1998-12-08 2009-08-20 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU774902B2 (en) 1998-12-28 2004-07-15 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
JP4832646B2 (ja) 1999-03-12 2011-12-07 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
EP1177301B1 (fr) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
EP1220925B8 (fr) 1999-09-20 2008-04-23 Sanofi Pasteur Limited Antigenes de chlamydia , fragments d'adn correspondants et utilisations
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (fr) 1999-12-22 2001-06-28 Aventis Pasteur Limited Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
WO2002095413A2 (fr) * 2001-05-23 2002-11-28 The University Of British Columbia Chlamydia hote contenant un phage, impliquee dans les maladies vasculaires
DE102006003814A1 (de) * 2006-01-26 2007-08-02 Sirs-Lab Gmbh Verfahren zur in-vitro-Diagnose von Chlamydophila pneumoniae Infektionen
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0784059B1 (fr) * 1994-09-20 2009-02-11 Hitachi Chemical Co., Ltd. Polynucleotides codantes pour une polypeptide antigenique de chlamydia pneumoniae
CN100390283C (zh) * 1997-11-21 2008-05-28 根瑟特公司 肺炎衣原体的基因组序列和其多肽,片段以及其用途特别是用于诊断、预防和治疗感染
KR100735652B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
EP1133572A4 (fr) 1998-11-12 2005-06-15 Univ California Sequence genomique de chlamydia pneumoniae
KR20090088972A (ko) 1998-12-08 2009-08-20 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1177301B1 (fr) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
EP1220925B8 (fr) 1999-09-20 2008-04-23 Sanofi Pasteur Limited Antigenes de chlamydia , fragments d'adn correspondants et utilisations
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (fr) 1999-12-22 2001-06-28 Aventis Pasteur Limited Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae

Also Published As

Publication number Publication date
US7132512B2 (en) 2006-11-07
CA2359354A1 (fr) 2000-08-10
EP1149162A2 (fr) 2001-10-31
WO2000046359A3 (fr) 2000-12-07
US20040029806A1 (en) 2004-02-12
CA2359354C (fr) 2008-07-08
EP1149162B1 (fr) 2009-03-11
AU2119200A (en) 2000-08-25
WO2000046359A2 (fr) 2000-08-10
DE60041753D1 (de) 2009-04-23
ATE425248T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
GB9902555D0 (en) Medicament
ZA200202306B (en) Topical treatment of streptococcal infections.
WO2001092288A3 (fr) Composes de cobalamine utilises comme agents antibiotiques et comme agents d'imagerie
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
MX236443B (es) Combinacion de bacterias de acido lactico y su uso para la prevencion y/o tratamiento de infecciones y condiciones inflamatorias.
GB0025173D0 (en) Therapeutic agents
FR11C0037I1 (fr)
WO2001045679A3 (fr) Utilisation d'agents chimiotherapeutiques
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
AU3227700A (en) Skin sanitizing compositions
ZA200108912B (en) Attenuated microorganisms for the treatment of infection.
CA2368574A1 (fr) Compositions destinees a la prevention et au traitement de l'allergie de type i
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2000058475A3 (fr) Proteines
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EP1303300A4 (fr) Compositions et procedes de traitement de la candidiase
ZA200109845B (en) Hair treatment compositions.
GB0025688D0 (en) Macrolides
WO2002057281A3 (fr) Aminoglycosides utilises comme antibiotiques
AU2768697A (en) Acyl urea compounds for the treatment of coccidioidomycosis in warm-blooded animals
AU2811400A (en) Stable formulation containing fumagillin
MD980129A (en) Antiherpetic remedy
PL355113A1 (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)